Bioasis posted a Corporate Presentation from April 2018 to the Investors Page of their website. Thanks to Frohlir944 over on Stockhouse for first posting. Great info in the presentation including anticipated pipeline timelines for xB3-001, -002, -007 and -008. The presentation really highlights that advantages and superiority of xB3 over competitor BBB crossing technologies.  

Slides 19-20 present a very detailed layout of the xB3-001 program timeline/target milestones and some proposed details on the FDA pre-IND (Type B) meeting in October 2018 in advance of the Phase 1 study. xB3-001 non-human primate PET studies planned for Q2 2018 and clinical manufacturing beginning Q2 2018. We should have some news soon. 

From slide 15: "Thom, et al. J. Cereb. Blood Flow Metab. 2018 (manuscript accepted). This might be the MedImmune collaboration study. I checked the journal website and don't see it posted online yet. I look forward to seeing this published study.

Great job on the presentation team Bioasis!

BearDownAZ